News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (341 of 400). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (15 of 400). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (44 of 400). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 288 of 400 items have one.
Minnesota Paid Leave Program Launches Statewide January 1, 2026, Covering Leave to Care for an Ill Family Member
The Minnesota Department of Employment and Economic Development (DEED) and Gov. Tim Walz announced that the state's Paid Leave program, created by a 2023 law, launches statewide on January 1, 2026, providing eligible workers paid, job-protected time off for major life events including caring for an ill family member. Early applications for 2025 births opened Dec. 3, 2025; up to 20,000 Minnesotans were expected to apply in December and January. Small employers pay reduced premium rates and may qualify for grants to cover staffing costs during an employee's leave. The Minnesota Department of Revenue separately states that beginning January 2026 the program provides eligible individuals with medical or family leave.
Why it matters: Minnesota's statewide Paid Leave program launches January 1, 2026, providing eligible workers with paid, job-protected time off for major life events, including caring for an ill family member.
Read at Minnesota Department of Employment and Economic Development (DEED); Minnesota Department of Revenue → Archived copy (24 Feb 2026), Internet ArchiveNew AI technology can provide rapid and reliable dementia diagnosis
Researchers at Örebro University have developed two new AI models that can analyze the brain's electrical activity and accurately distinguish between healthy individuals and patients with dementia, including Alzheimer's disease.
Why it matters: Researchers developed AI models analyzing brain electrical activity to distinguish healthy individuals from dementia and Alzheimer's patients.
Pill form of semaglutide fails to slow Alzheimer's in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.
Why it matters: A pill form of semaglutide failed to slow Alzheimer's disease progression in a large trial, Novo Nordisk announced on Nov. 24.
Read at Medical Xpress → Archived copy (6 Jan 2026), Internet ArchiveNovel discovery reveals how brain protein OTULIN controls tau expression and could transform Alzheimer's treatment
Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in Alzheimer's disease. …
Why it matters: Scientists uncovered a surprising mechanism by which the brain enzyme OTULIN controls tau expression, which could transform Alzheimer's treatment.
Read at Medical Xpress → Archived copy (25 Nov 2025), Internet ArchiveAlzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in more than 3,800 people with early symptomatic Alzheimer's did not meet the primary endpoint of significantly slowing disease progression, despite improving some Alzheimer's-related biomarkers. Novo Nordisk ended its Alzheimer's trials for semaglutide, including the injectable version.
Why it matters: A high-profile failure for the theory that GLP-1 weight-loss drugs could treat Alzheimer's, dampening near-term hopes for repurposing this popular drug class for dementia.
Read at Alzheimer's Association → Archived copy (30 Jul 2026), Internet ArchiveJ&J's Novel Alzheimer's Drug Fails in Key Trial, Dimming Hopes for a Hot Target
Johnson & Johnson terminated its mid-stage trial of posdinemab, a tau-targeting antibody, after an early analysis showed it was not outperforming placebo in slowing Alzheimer's progression.
Why it matters: A setback for the broader strategy of targeting tau protein rather than amyloid, a drug class also being pursued by Biogen, UCB, and Voyager Therapeutics.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (1 Mar 2026), Internet ArchiveAPOE gene raises delirium risk even without dementia, global analysis reveals
A major genetic risk factor for delirium has been identified in a study that analyzed the DNA of more than 1 million people worldwide.
Why it matters: A study analyzing DNA from over 1 million people worldwide identified a major genetic risk factor for delirium.
Genetic risk combined with cardiovascular factors may help predict and delay dementia
Combining genetic risk with cardiovascular disease risk factors—such as high LDL cholesterol, obesity, and hypertension—may predict who is more likely to develop dementia, according to a new study led by UC San Francisco.
Why it matters: Combining genetic risk with cardiovascular disease risk factors—such as high LDL cholesterol, obesity, and hypertension—may predict who is more likely to develop dementia.
Read at Medical Xpress → Archived copy (22 Jan 2026), Internet ArchiveSimple blood test may someday allow for diagnosis of LATE dementia during life
Jijing Wang, Ph.D., and Hyun-Sik Yang, MD, of the Department of Neurology at Mass General Brigham, are the lead and senior authors of a paper published in Molecular Neurodegeneration titled "Plasma TDP-43 is a potential biomarker for advanced limbic-predominant…
Why it matters: A simple blood test measuring plasma TDP-43 may someday enable doctors to diagnose advanced LATE dementia during a patient's life.
Read at Medical Xpress → Archived copy (21 Nov 2025), Internet ArchiveHow AI can create a virtual programmable human and revolutionize drug discovery
From idea, to lab, to clinic, to approval—it's a long and expensive process to bring a drug to market. It also rarely succeeds.
Why it matters: AI can create a virtual programmable human and revolutionize drug discovery, which is key because bringing a drug to market is a long, expensive process that rarely succeeds.
Read at Medical Xpress → Archived copy (17 Dec 2025), Internet ArchiveFollow new items in a feed reader: Atom feed.
Last updated